It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
The review found no eligible studies for this question.
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).